Delta 9 Reports Financials for Q3 2019 and Announces Grant of Stock Options

Delta 9 Reports Financials for Q3 2019 and Announces Grant of Stock Options

WINNIPEG, MB – November 13, 2019 – DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for the three-month and nine-month period ending September 30, 2019.
Financial Highlights for Q3, 2019

  • Operating revenues of $6.7 million for the third quarter of 2019, up 432%, from $1,251,213 for the same quarter last year.
  • Adjusted EBITDA[1] was $(849,760) compared to $(2,551,710) in Q3, 2018.
  • Gross profit[2] of $2.0 million for the third quarter of 2019, up 550%, from $312,480 for the same quarter last year.
  • Gross profit margin was 31% for Q3, 2019.

Financial Highlights for the nine months of 2019

  • Record operating revenues of $21.2 million, up 821%, from $2.3 million for the same period last year.
  • Gross profit2 of $6.8 million, up 799%, from $756,644 for the same period last year.
  • Gross profit margin was 32% for the nine months of 2019.

“Management would point to the significant year over year increases in net revenue as a positive indication that the Company’s initial quarters of sales in the recreational use cannabis market have been able to contribute significant revenue growth,” said John Arbuthnot, CEO of Delta 9. “Management attributes the decrease in sequential quarterly revenue to a timing issue with revenue in its business to business (B2B) division which was down from the 2nd quarter of 2019.”

The Company’s retail division generated $4.4 million in revenue in the 3rd quarter of 2019 which was up 24% or $840,208 sequentially. The wholesale division generated $2.2 million in revenue for the same period and was down 23% or $684,138.

“Delta 9 will continue to drive sustainable long-term shareholder value by leveraging its strong brand positioning in Western Canadian markets, expanding our various wholesale supply contracts and scaling up our cultivation operations,” said John Arbuthnot, CEO of Delta 9. “We are taking a responsible and compliant approach to growing our business to build an authentic Delta 9 brand as we pursue retail opportunities in the Western Canadian market place.”

3rd Quarter Operational Highlights

  • The company entered into a binding letter of intent to acquire two retail stores in Alberta that continues the strategy of establishing a chain of Delta 9 branded retail stores across Canada. Delta 9’s goal is to add an additional 12 retail stores over the next 24 months.
  • The newest Delta 9 Cannabis Store is the largest cannabis retail store in the Thompson, Manitoba area, offering customers an open and modern shopping décor, highly trained staff and a wide range of products, including dried cannabis flower, cannabis oil and a full assortment of cannabis accessories.
  • The Company installed and began crop production of cannabis in an additional 48 of its proprietary “Grow Pods”, bringing its total number of Grow Pods in production to 202 within its Winnipeg production facility (the “Delta Facility”).
    • The additional 48 Grow Pods will increase production by 1,150 kilograms per year of dried cannabis flower production, bringing the Company’s overall anticipated production capacity to 5,350 kilograms of dried cannabis flower per year.
  • There is another 95 Grow Pods in place and ready for planting once Delta 9 receives approval from Health Canada, which is expected shortly. This will bring the total Grow Pods in production to 297 within the Delta Facility.
    • The Company is continuing with its planned Phase II expansion of the Delta Facility to increase cannabis production to 16,500 kilograms per year.
  • After successfully passing all inspections, Delta 9 received a renewal of its cannabis cultivation license for a three-year term after fulfilling Health Canada's rigorous specifications.

Summary of Quarterly Results:

Consolidated Statement of Net Loss

Q3 2019

Q2 2019

Q1 2019

Q4 2018

Revenue

$6,662,137

$8,886,155

$5,632,184

$5,270,217

Cost of Sales

4,628,070

5,936,975

3,815,930

4,015,644

Gross Profit Before Unrealized Gain From Changes In Biological Assets

2,034,067

2,949,180

1,816,254

1,254,573

Unrealized gain from changes in fair value of biological assets (Net)

1,388,863

586,366

2,406,735

2,087,367

Gross Profit (Loss)

$3,422,930

$3,535,546

$4,222,989

$3,341,940

 

 

 

 

 

Expenses

 

 

 

 

General and Administrative

2,681,388

3,075,803

3,451,900

3,296,351

Sales and Marketing

1,151,158

1,324,537

969,202

1,389,241

Share Based Compensation

215,456

244,848

748,067

807,834

Total Operating Expenses

$4,048,002

$4,645,188

$5,169,169

$5,493,426

 

 

 

 

 

Adjusted EBITDA (Loss) 1

(849,760)

(663,705)

(1,978,778)

(2,815,412)

Income (Loss) from Operations

$(625,072)

$(1,109,642)

$(946,180)

$(2,151,486)

Other Income/ Expenses

$(642,190)

$(206,231)

$17,260,525

$69,033

Net Income (Loss)

$(1,267,262)

$(1,315,873)

$16,314,345

$(2,082,453)

Basic and Diluted Earnings (Loss) Per Share

$(0.02)

$(0.01)

$0.19

$(0.02)

  1. Adjusted EBITDA is a non-IFRS measure, and is calculated as earnings before interest, tax, depreciation and amortization, share-based compensation expense, fair value changes and other non-cash items.

 

 
The following chart provides a breakdown of the Company’s revenue by segment:

Revenue from the Sale of Cannabis

Three-month period ending September 30, 2019

Three-month period ending June 30, 2019

Wholesale Cannabis Revenue

$2,233,509

$2,917,647

Retail Cannabis Revenue

4,359,614

3,519,406

Medicinal Cannabis Revenue

66,770

87,416

 

 

 

Revenue from Other categories

 

 

Business to business activities

222,944

2,165,167

Merchandise and cannabis devices

158,721

184,164

Other

31,010

62,976

 

 

 

Sub total

$7,072,568

$8,936,776

 

 

 

(Less) Excise Taxes

410,431

50,621

 

 

 

Net Revenue

$6,662,137

$8,886,155

 

Discussion of Operations:

 

Key Performance Indicators

For the three-month period ending September 30, 2019

For the three-month period ending June 30, 2019

Production/ Wholesale Unit

 

 

Total Grams Produced

871,516

675,233

Direct Production Cost Per Gram*

$1.08

$1.05

Total Cost Per Gram**

$1.21

$1.21

Total Grams Released for Sale

519,596

565,599

Total Grams Sold (Medical and Recreational)

548,981

527,693

Avg Selling Price per Gram

$4.19

$5.63

 

 

 

Retail Unit

 

 

Total Grams Sold (Retail)

349,410

282,336

Avg Selling Price per Gram

$12.47

$12.42

Number of Transactions Processed

108,438

84,882

Avg Transaction Size

$41.67

$41.46


*Direct Production Cost per gram includes direct labour, nutrients, utilities, growing materials and supplies costs
**Total Cost per gram includes Direct Production Cost per gram plus processing labour, packaging, bottling, and labelling costs

A comprehensive discussion of Delta 9’s financial position and results of operations is provided in the Company’s Management Discussion & Analysis for the third quarter and nine months of 2019 filed on SEDAR and can be found at www.sedar.com.

Q3 Results 2019 Conference Call


Delta 9 has scheduled a conference call to discuss the results for third quarter of 2019. The conference call will be hosted November 14, 2019 at 9:00 a.m. Eastern Time by John Arbuthnot, Chief Executive Officer and Jim Lawson, Chief Financial Officer, followed by a question and answer period.

DATE:

November 14, 2019

TIME:

9:00 a.m. Eastern Time

DIAL IN #

1-888-886-7786

REPLAY:

1-877-674-6060
Available until 12:00 midnight Eastern Time, February 28, 2020

REPLAY PASSCODE:

107644 #


Grant of Stock Options

Delta 9 also wishes to announced that it has granted, effective today, an aggregate of 3,000,000 stock options (each an "Option") to certain directors, officers, employees and consultants of the Company in accordance with the Company’s current stock option plan. Each Option is exercisable into one common share (a "Share") of the Company at a price of $0.55 per Share for a period of five years from the date of grant, being today. The Options will vest over twelve months, with 1,500,000 (50%) vesting six months from the date hereof and the remaining 1,500,000 (50%) vesting 12 months from the date hereof.
“Stock Options play a key role in compensating our employees and aligning their interests with those of the shareholder,” said John Arbuthnot, CEO of Delta 9, “Delta 9 has an inclusive options program which allows for all eligible staff to receive options based on their position and performance. We are very proud of our staff’s operating performance to date; this grant will allow for over 185 eligible staff to receive stock options in Delta 9.”

For more information contact:
Investor & Media Contact:
Ian Chadsey VP Corporate Affairs
Mobile: 204-898-7722
E-mail: ian.chadsey@delta9.ca

 
About Delta 9 Cannabis Inc.
Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. The company sells cannabis products through its wholesale and retail sales channels and sells its cannabis grow pods to other businesses. Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9's shares trade on the Toronto Stock Exchange under the symbol "DN" and on the OTCQX under the symbol "VRNDF". For more information, please visit www.delta9.ca.


Disclaimer for Forward-Looking Information
 
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to the expansion of Delta 9’s wholesale supply contracts and scaling up its cultivation operations. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including all risk factors set forth in the annual information form of Delta 9 dated April 30, 2019 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
 

 

[1] The Company’s “Adjusted EBITDA” is a measure used by management that does not have any standardized meaning prescribed by International Financial Reporting Standards and may not be comparable to similar measures presented by other companies. Management defines the Adjusted EBITDA as the income (loss) from operations, as reported, before interest and tax, adjusted for removing share-based compensation expense, depreciation and amortization, and the fair value effects of accounting for biological assets and inventories. Management believes that Adjusted EBITDA, and the attribution of Adjusted EBITDA in the manner described above, provides meaningful and useful financial information as these measures demonstrate the performance of the Company’s operating businesses.

[2] The Company’s “gross profit” Is calculated before adjustments for changes in biological assets.

Previous article Delta 9 Enters Definitive Agreement to Acquire Two Alberta Retail Stores
Next article Delta 9 Enters into Binding Letter of Intent to Acquire Two Alberta Retail Stores

Profile can't be loaded

Hi. Welcome to Delta9 Cannabis

Enter Your Date of Birth

  • January
  • February
  • March
  • April
  • May
  • June
  • July
  • August
  • September
  • October
  • November
  • December
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31

    Your are still not of legal age to access this site and/or to purchase cannabis.

    Submit

    You must be of legal age in accordance with the law of your province to access this website and/or to purchase cannabis.

    By entering this site you agree to our terms and conditions and privacy policy.